Plenty of studies have assessed the association between intestinal metaplasia (IM) and gastric cancer risk, while the results were inconsistent. We aimed to assess the risk of gastric cancer among patients with IM. Systematic literature searches were conducted in PubMed, Embase and Cochrane databases. Baseline characteristics and outcomes from the included studies were extracted independently by two investigators. Either a fixed-effects or a random-effects model was used to composite the pooled OR for gastric cancer risk. Finally, a total of 21 studies, which comprised 402,636 participants and 4,535 gastric cancer patients, were finally included in the current meta-analysis. Compared with those participants without IM, IM patients were at a higher risk of gastric cancer (pooled OR 5 3.58, 95% CI 2.71-4.73). We observed that incomplete IM (pooled OR 5 9.48, 95% CI 4.33-20.78) but not complete IM (pooled OR 5 1.55, 95% CI 0.91-2.65) was significantly associated with a higher gastric cancer risk. Besides, it appeared that gastric cancer risk was higher among patients with IM in the corpus (pooled OR 5 7.39, 95% CI 4.94-11.06) than those with IM in the antrum only (pooled OR 5 4.06, 95% CI 2.79-5.91). And the pooled ORs for gastric noncardia cancer and gastric cardia cancer were 4.98 (95% CI 3.12-7.95) and 1.93 (95% CI 1.15-3.24), respectively. In conclusion, patients with IM were at a higher risk of gastric cancer, especially for incomplete IM and IM in the corpus. The current evidence supports the use of IM subtypes in the surveillance of gastric cancer.
Gastric cancer remains one of the most common malignancies in both sexes, and is the third leading cause of cancer mortality worldwide. 1 Helicobacter pylori (H. pylori) has been well recognized as the most important risk factor for gastric cancer, moreover, smoking and dietary factors such as high intake of salty food, preserved meat and alcohol, and low citrus fruit consumption are also associated with higher gastric cancer risk. [1] [2] [3] The survival rate for patients with gastric cancer remains poor, which is associated with the late stage of diagnosis. Thus, increasing early gastric cancer detection rate is an important approach to improve survival for gastric cancer, which suggests the importance of surveillance for patients with high risk of gastric cancer.
Gastric cancer commonly arises from a multiple process starting from chronic non-atrophic gastritis, usually associated with H. pylori infection, and followed by atrophic gastritis and intestinal metaplasia (IM), dysplasia and finally invasive carcinoma. 4, 5 Atrophic gastritis and intestinal metaplasia are common findings on endoscopy, which usually occur initially at antrum and then expand to corpus. 6 Moreover, IM has long been recognized as a heterogeneous lesion according to histology and types of mucin secreted, and can be classified as small intestinal type (complete IM) or colonic type (incomplete IM). 7 IM has been suggested to be an independent risk factor for gastric cancer by plenty of studies. 6, [8] [9] [10] [11] [12] [13] The annual incidence of gastric cancer among IM patients ranged from 0% to 10%, while most of the studies had small sample size. 14, 15 Moreover, studies have also suggested that the risk of gastric cancer among patients with IM was associated with the extension and subtypes (complete IM or incomplete IM). 6, 9, 12, 16, 17 Usually, IM in the corpus and incomplete IM were considered to be associated with higher gastric cancer risk compared with IM in the antrum only and complete IM. 18 Previous guideline recommended endoscopic surveillance for patients with extensive atrophy and/or IM, but did not recommend the use of subtyping IM. 19 In the current meta-analysis, we aimed to systematically assess the risk of gastric cancer among patients with IM.
Methods

Literature search and study selection
The protocol for this systematic review was based on the PRISMA statement. 20 A systematic literature search was conducted in the PubMed, Embase and Cochrane databases up to December 2016 for possible articles. The following terms were used in the literature search: ("gastric cancer" or "stomach cancer" or "gastric adenocarcinoma" or "stomach adenocarcinoma" or "gastric carcinoma" or "stomach carcinoma" or "gastric tumor" or "stomach tumor" or "gastric malignancy" or "stomach malignancy") AND ("intestinal metaplasia" or "IM"). References of the included studies in this systematic review and relevant reviews were also searched for the potentially missed articles. The authors carefully examined the retrieved reports to exclude duplicated studies. Titles and abstracts of the retrieved articles were first scanned, and then full articles were reviewed to include eligible studies. Two investigators independently evaluated the eligibility of studies for inclusion according to the following criteria: (i) the study was observational study; (ii) the study investigated the association between IM and risk of gastric cancer; (iii) the study reported the risk estimate as an odds ratio (OR), standardized incidence ratio (SIR), relative risk (RR) or hazard ratio (HR) with a 95% CI, or the risk estimate could be calculated. For overlapped data, only the most detailed or recent information was extracted. We only included studies published in English.
Data extraction
Two reviewers independently conducted the data extraction procedure, and discrepancies were resolved by a third investigator. The following information was extracted from each study: first author, publication year, study design, country of origin, sample size of the study, number of IM patients, number of gastric cancer patients, method of IM diagnosis, risk estimates and adjusted factors. Ratios that reflected the greatest degree of control for potential confounders were adopted in this systematic review.
Statistical analysis
Study-specific risk estimate for IM and gastric cancer risk was pooled using either a random-effects model or a fixedeffects model according to extent of heterogeneity across individual studies. v 2 test and I 2 test were used to evaluate heterogeneity, and p 0.05 and/or I 2 > 50% indicates significant heterogeneity. 21 The primary meta-analysis was conducted to investigate the risk of gastric cancer among patients with IM. Sensitivity and subgroup analyses were further conducted to explore source of heterogeneity and to evaluate the potential effect modification of factors including subtypes of IM, subtypes of gastric cancer, study design, country of origin and study quality. To evaluate the publication bias risk, Begg's funnel plots and Egger's test were performed. All analyses were conducted using the Stata software (V.11.0; StataCorp, College Station, TX), and p values <0.05 was considered significant for all tests.
Results
Description of the included studies
Literature searches in PubMed, Embase and Cochrane databases resulted in inclusion of 2047 articles, of which 41 were potentially relevant reports for further review. A total of 20 reports were excluded for the following reasons: did not report association between IM and risk of gastric cancer (n 5 10); insufficient data (n 5 5); not original articles (n 5 4); duplicate data (n 5 1). As shown in Figure 1 , 21 studies were finally included in the current systematic review and meta-analysis. 6, [8] [9] [10] [11] [12] [13] [15] [16] [17] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] The characteristics of the included studies were suggested in Table 1 . Most of the included studies were conducted in East Asia (n 5 14), and the remaining 7 studies were performed in Europe or USA. Eleven of the included studies were cohort studies, while 8 were case-control studies and 2 were cross-section studies. Sample size of the included studies ranged from 63 to 288,167, and number of gastric cancer patients ranged from 7 to 1,470. All the studies enrolled both male and female participants, and histopathology was adopted for IM diagnosis in all the included studies. Most of the included studies assessed the risk of gastric cancer among patients with IM compared with those without IM or general population, while 3 studies used atrophic gastritis as control group.
Gastric cancer risk among the patients with IM
A total of 21 studies comprising 402,636 participants and 4,535 gastric cancer patients evaluated the risk of gastric cancer among patients with IM. The pooled analysis represented an OR of 3.58 (95% CI 2.71-4.73) with significant heterogeneity (I 2 5 83.4%, p < 0.001) (Fig. 2) , indicating a higher gas- Sensitivity analysis was performed excluding those 3 studies, since atrophic gastritis is also associated with a higher gastric cancer risk, and the pooled OR was 3.60 (95% CI 2.70-4.81), and no publication bias was observed (P Begg's test 5 0.363, P Egger's test 5 0.200).
We observed different gastric cancer risks according to distribution and subtypes of IM. Compared with patients without IM, the pooled OR for patients with IM in the antrum only was 4.06 (95% CI 2.79-5.91) (Fig. 3a) , while gastric cancer risk appeared to be higher among patients with IM in the corpus (pooled OR 5 7.39, 95% CI 4.94-11.06) (Fig. 3b) . Besides, incomplete IM was associated with a significantly higher risk of gastric cancer (pooled OR 5 9.48, 95% CI 4.33-20.78) (Fig. 3c) , while no significant association was found between complete IM and gastric cancer risk (pooled OR 5 1.55, 95% CI 0.91-2.65) (Fig. 3d) .
Subgroup analyses were also performed according to subtypes of gastric cancer, study design, country of origin, sample size and study quality of the included studies, as shown in 
Discussion
The current large-scale meta-analysis included 21 with 402,636 participants and 4,535 gastric cancer patients, and systematically evaluated gastric cancer risk among patients with IM. The pooled results indicated that patients with IM were at a higher gastric cancer risk (OR 5 3.58). Subgroup analyses support the use of extension and subtypes of IM in predicting gastric cancer risk. Incomplete IM (OR 5 9.48) but not complete IM (OR 5 1.55) was significantly associated with a higher gastric cancer risk, and patients with IM in the corpus (OR 5 7.39) appeared to have a higher gastric cancer risk than IM the antrum only (OR 5 4.06).
Incomplete IM (colonic type) has been recognized to be the most advanced stage of IM and is a useful marker to identify subjects with high gastric cancer risk. 7 However, as indicated by a recent guideline, extensive atrophy and/or IM should be used for clinical practice, while subtyping of IM was not recommended, because the evidence was thought to be "limited and inconsistent" and "subtyping of IM requires the use of immunohistochemistry techniques that are not widespread in routine diagnostic." 19 The current metaanalysis included 6 studies exploring gastric cancer risk in incomplete IM patients and the pooled result support the use of incomplete IM in predicating gastric cancer risk. Though most of the included studies used Alcian blue and high iron diamine (AB/HID) method to categorise IM subgroups, it was suggested that the classification of IM (complete type or incomplete type) does not always require immunohistochemistry method. 9 A recent study used hematoxylin and eosin (HE), the routine histological stain method in subtyping of IM, and reported that IM subtypes can be easily detected. 9 Consistent with the previous studies, the current metaanalysis also supports evaluating the extent of IM. As suggested by the study of Cassaro et al., incomplete IM prevalence was much higher in patients with extensive IM (IM observed in 4 or more of 12 biopsy specimens) than those with rare IM (3 or fewer biopsy specimens). 16 They reported that irrespective of IM subtype, extensive IM was associated with a higher gastric cancer risk. Considering that in clinical practice, sometimes only a few biopsies are used for histopathology examination, subtyping of IM would be beneficial for predicating gastric cancer risk.
Plenty of studies have investigated risk factors for gastric cancer, and some reports suggested that risk factors of GNCC were different from those of GCC. 33, 34 For example, H. pylori infection has been well recognized to be a significant risk factor of GNCC, while the association between H. pylori and cardia gastric cancer incidence remains unclear. 35 Moreover, smoking, intake of salty, preserved meat and smoked food are risk factors of GNCC, while low citrus fruit intake, gastroesophageal reflux disease (GERD) and obesity have been suggested to be associated with higher GCC risk. 3, 11 In the current meta-analysis, the pooled OR for the association between IM and GNCC was 4.98, which is higher compared with GCC (pooled OR 5 1.93). This further supports the difference between pathophysiology in the development of GNCC and GCC.
Our meta-analysis comprehensively analyzed studies evaluating the association between IM and gastric cancer risk, providing further evidence for the use of IM in predicting gastric cancer risk. This may be important in clinical practice, such as surveillance of gastric cancer. However, there are still some limitations in the current study. First, the number of studies involved in some subgroup analyses was relatively small, thus the results might be less accurate. Second, the controls were not uniformly defined, most of the included studies used those subjects without IM as control group, while some used atrophic gastritis or general as control group. Sensitivity analysis was then conducted by removing those studies using atrophic gastritis as control group, which partially resolved this problem. Third, the heterogeneity across studies could not be fully explained, and publication bias may exist in the pooled analysis of all the 21 studies. Besides, this meta-analysis was not able to control for confounding factors in the included studies, which may resulted in inaccurate result. Moreover, for the cohort studies, follow up time might influence the risk of gastric cancer for IM patients, while only the mean or median follow-up years were reported and the follow-up time for individuals were not available. A future individual participant data metaanalysis might contribute to solve this problem. And all the included studies were conducted in Europe, USA or East Asia, thus the results should be explained with caution for other population.
In conclusion, patients with IM were at a higher risk of gastric cancer, especially for incomplete IM and IM in the corpus. The current evidence supports the use of IM subtypes in the surveillance of gastric cancer. Large sample size was larger than 1,000 patients while small sample size was 1,000.
